We are live on ! Find out more
AVTX icon

Avalo Therapeutics
AVTX

43 hedge funds and large institutions have $34.7M invested in Avalo Therapeutics in 2022 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 18 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% less ownership

Funds ownership: 0.02% → 0.02% (-0%)

34% less funds holding

Funds holding: 65 → 43 (-22)

38% less capital invested

Capital invested by funds: $56.2M → $34.7M (-$21.5M)

78% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 27

78% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 18

Holders
43
Holders Change
-22
Holders Change %
-33.85%
% of All Funds
0.72%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
4
Reduced
18
Closed
27
Calls
$7K
Puts
–
Net Calls
+$7K
Net Calls Change
+$13K

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$470K
2
E
Ergoteles
New York
+$132K
3
Goldman Sachs
Goldman Sachs
New York
+$58.9K
4
Citadel Advisors
Citadel Advisors
Florida
+$28.1K
5
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
+$20.1K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$1.17M
2
BFM
Boothbay Fund Management
New York
-$869K
3
IC
Ikarian Capital
Texas
-$554K
4
IHAM
Integral Health Asset Management
New York
-$507K
5
OM
Opaleye Management
Massachusetts
-$467K

AVTX Hedge Fund Activity: Q2 2022 in Review

43 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Avalo Therapeutics (AVTX) for Q2 2022, worth a combined $34.7M — down 38% from $56.2M a quarter earlier.

Sellers outnumbered buyers: 27 funds closed out of AVTX and 6 opened new positions — a net loss of 21 holders — while 18 trimmed existing stakes and 4 added.

The largest buyer was Millennium Management, opening a new position worth an estimated $470K. The largest seller was BlackRock, cutting an estimated $1.17M.

  • 43 institutional investors held Avalo Therapeutics (AVTX) as of Q2 2022, down from 65 in Q1 2022.
  • Funds reported $34.7M of Avalo Therapeutics stock for Q2 2022, down 38% quarter-over-quarter.
  • 6 funds opened new Avalo Therapeutics positions in Q2 2022 and 27 closed out, a net change of -21 holders.
  • The largest Avalo Therapeutics buyer in Q2 2022 was Millennium Management, an estimated $470K added.
  • The largest Avalo Therapeutics seller in Q2 2022 was BlackRock, an estimated $1.17M sold.

Based on aggregated 13F filings for Q2 2022.